{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:50:14Z","timestamp":1760921414861,"version":"build-2065373602"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurosurgery Clinics of North America"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.nec.2020.12.001","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T10:34:36Z","timestamp":1613730876000},"page":"181-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pediatric Gliomas"],"prefix":"10.1016","volume":"32","author":[{"given":"Sophie M.","family":"Peeters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yagmur","family":"Muftuoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0038-1635106","article-title":"Gliomas in Children","volume":"38","author":"Filbin","year":"2018","journal-title":"Semin Neurol"},{"issue":"9","key":"10.1016\/j.nec.2020.12.001_bib2","article-title":"Infantile\/Congenital High-Grade Gliomas: Molecular Features and Therapeutic Perspectives","volume":"10","author":"Ceglie","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.nec.2020.12.001_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-0035-1570491","article-title":"The changing landscape of pediatric low-grade gliomas: clinical challenges and emerging therapies","volume":"47","author":"Guerreiro Stucklin","year":"2016","journal-title":"Neuropediatrics"},{"issue":"9","key":"10.1016\/j.nec.2020.12.001_bib4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11910-014-0474-4","article-title":"The molecular landscape of pediatric brain tumors in the next-generation sequencing era","volume":"14","author":"Firme","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"9","key":"10.1016\/j.nec.2020.12.001_bib5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/neuonc\/noaa035","article-title":"Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response","volume":"22","author":"Aichm\u00fcller","year":"2020","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.nec.2020.12.001_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11060-017-2393-0","article-title":"Pediatric high-grade glioma: current molecular landscape and therapeutic approaches","volume":"134","author":"Braunstein","year":"2017","journal-title":"J\u00a0Neurooncol"},{"issue":"4","key":"10.1016\/j.nec.2020.12.001_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","article-title":"Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas","volume":"37","author":"Ryall","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.nec.2020.12.001_bib8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00401-020-02142-w","article-title":"Histone H3 wild-type DIPG\/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation","volume":"139","author":"Castel","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.nec.2020.12.001_bib9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","article-title":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","volume":"130","author":"Castel","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nec.2020.12.001_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fonc.2015.00147","article-title":"Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma","volume":"5","author":"Buczkowicz","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.nec.2020.12.001_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fonc.2018.00169","article-title":"The integration of biology into the treatment of diffuse intrinsic pontine glioma: a review of the North American clinical trial perspective","volume":"8","author":"Clymer","year":"2018","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.nec.2020.12.001_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.nec.2020.12.001_bib13","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(14)71206-9","article-title":"Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies","volume":"16","author":"Northcott","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/noz142","article-title":"WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial","volume":"22","author":"Varlet","year":"2020","journal-title":"Neuro Oncol"},{"issue":"7697","key":"10.1016\/j.nec.2020.12.001_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.nec.2020.12.001_bib16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nec.2020.12.001_bib17","first-page":"97","article-title":"Chapter 6 - Molecular classification of gliomas","volume":"vol. 134","author":"Masui","year":"2016"},{"issue":"7384","key":"10.1016\/j.nec.2020.12.001_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.nec.2020.12.001_bib19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","article-title":"Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma","volume":"22","author":"Sturm","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.nec.2020.12.001_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib21","first-page":"156","article-title":"Independent association of extent of resection with survival in patients with malignant brain astrocytoma","volume":"110","author":"McGirt","year":"2009","journal-title":"J\u00a0Neurosurg"},{"issue":"6","key":"10.1016\/j.nec.2020.12.001_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/CCO.0000000000000577","article-title":"Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets","volume":"31","author":"Aziz-Bose","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00381-019-04363-1","article-title":"Clinical trials for diffuse intrinsic pontine glioma: the current state of affairs","volume":"36","author":"Rechberger","year":"2020","journal-title":"Childs Nerv Syst"},{"issue":"5","key":"10.1016\/j.nec.2020.12.001_bib24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ccell.2019.04.004","article-title":"Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas","volume":"35","author":"Krug","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.nec.2020.12.001_bib25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41419-020-02800-7","article-title":"Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells","volume":"11","author":"Wiese","year":"2020","journal-title":"Cell Death Dis"},{"issue":"4\u20136","key":"10.1016\/j.nec.2020.12.001_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1387\/ijdb.150334sv","article-title":"In silico analysis of histone H3 gene expression during human brain development","volume":"60","author":"Ren","year":"2016","journal-title":"Int J Dev Biol"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s40478-018-0614-1","article-title":"Transcriptomic and epigenetic profiling of \u201cdiffuse midline gliomas, H3 K27M-mutant\u201d discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location","volume":"6","author":"Castel","year":"2018","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"10.1016\/j.nec.2020.12.001_bib28","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/0008-5472.CAN-18-3441","article-title":"Intratumoral genetic and functional heterogeneity in pediatric glioblastoma","volume":"79","author":"Hoffman","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.nec.2020.12.001_bib29","doi-asserted-by":"crossref","first-page":"15816","DOI":"10.1038\/ncomms15816","article-title":"The genomic landscape of tuberous sclerosis complex","volume":"8","author":"Martin","year":"2017","journal-title":"Nat Commun"},{"issue":"9861","key":"10.1016\/j.nec.2020.12.001_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.nec.2020.12.001_bib31","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.nec.2020.12.001_bib32","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.nec.2020.12.001_bib33","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2017.73.0242","article-title":"Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management","volume":"35","author":"Sturm","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.nec.2020.12.001_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fonc.2016.00259","article-title":"Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma","volume":"6","author":"Ricker","year":"2016","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.nec.2020.12.001_bib35","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/JCO.2003.03.043","article-title":"Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology","volume":"21","author":"Laithier","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.nec.2020.12.001_bib36","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A\u00a0phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro Oncol"},{"issue":"15_suppl","key":"10.1016\/j.nec.2020.12.001_bib37","doi-asserted-by":"crossref","first-page":"10504","DOI":"10.1200\/JCO.2017.35.15_suppl.10504","article-title":"A\u00a0phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study","volume":"35","author":"Fangusaro","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.nec.2020.12.001_bib38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/neuonc\/nou329","article-title":"Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth","volume":"17","author":"Kaul","year":"2015","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.nec.2020.12.001_bib39","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.nec.2020.12.001_bib40","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"issue":"21","key":"10.1016\/j.nec.2020.12.001_bib41","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MOP.0000000000000562","article-title":"Review of molecular classification and treatment implications of pediatric brain tumors","volume":"30","author":"Guerreiro Stucklin","year":"2018","journal-title":"Curr Opin Pediatr"},{"issue":"25","key":"10.1016\/j.nec.2020.12.001_bib43","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1200\/JCO.2016.71.8726","article-title":"Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas","volume":"35","author":"Lassaletta","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.nec.2020.12.001_bib44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bpa.12081","article-title":"BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors","volume":"24","author":"Prabowo","year":"2014","journal-title":"Brain Pathol"},{"issue":"6","key":"10.1016\/j.nec.2020.12.001_bib46","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00401-013-1100-2","article-title":"Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells","volume":"125","author":"Koelsche","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1016\/j.nec.2020.12.001_bib47","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1158\/1541-7786.MCR-17-0507","article-title":"Desmoplastic Infantile Ganglioglioma\/Astrocytoma (DIG\/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations","volume":"16","author":"Wang","year":"2018","journal-title":"Mol Cancer Res"},{"issue":"9","key":"10.1016\/j.nec.2020.12.001_bib48","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.2014.58.3922","article-title":"BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma","volume":"33","author":"Mistry","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.nec.2020.12.001_bib49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s10014-019-00340-3","article-title":"Molecular genetics and therapeutic targets of pediatric low-grade gliomas","volume":"36","author":"Tateishi","year":"2019","journal-title":"Brain Tumor Pathol"},{"issue":"24","key":"10.1016\/j.nec.2020.12.001_bib50","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I\/IIa Study","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib51","doi-asserted-by":"crossref","first-page":"OF5","DOI":"10.1158\/2159-8290.CD-NB2016-140","article-title":"Dabrafenib Effective in Pediatric Glioma","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.nec.2020.12.001_bib52","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","article-title":"Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.nec.2020.12.001_bib53","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1056\/NEJMcibr1013704","article-title":"Resistance to BRAF inhibition in melanomas","volume":"364","author":"Solit","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.nec.2020.12.001_bib54","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/WCO.0000000000000027","article-title":"Next-generation molecular genetics of brain tumours","volume":"26","author":"Suv\u00e0","year":"2013","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1084\/jem.20171046","article-title":"Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy","volume":"215","author":"Chheda","year":"2018","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.nec.2020.12.001_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140378","article-title":"Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma","author":"Mueller","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.nec.2020.12.001_bib57","doi-asserted-by":"crossref","first-page":"eaau5935","DOI":"10.1126\/sciadv.aau5935","article-title":"Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma","volume":"4","author":"Stafford","year":"2018","journal-title":"Sci Adv"},{"issue":"6134","key":"10.1016\/j.nec.2020.12.001_bib58","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1126\/science.1232245","article-title":"Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma","volume":"340","author":"Lewis","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.nec.2020.12.001_bib59","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36696","article-title":"H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers","volume":"7","author":"Fang","year":"2018","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.nec.2020.12.001_bib60","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nm.4296","article-title":"Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas","volume":"23","author":"Piunti","year":"2017","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.nec.2020.12.001_bib61","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-1076-0","article-title":"Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling","volume":"3","author":"Chen","year":"2020","journal-title":"Commun Biol"},{"issue":"12","key":"10.1016\/j.nec.2020.12.001_bib63","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/nm.1888","article-title":"BMP type I receptor inhibition reduces heterotopic [corrected] ossification","volume":"14","author":"Yu","year":"2008","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.nec.2020.12.001_bib64","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.semradonc.2014.06.003","article-title":"The genetic signatures of pediatric high-grade glioma: no longer a one-act play","volume":"24","author":"Diaz","year":"2014","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"10.1016\/j.nec.2020.12.001_bib65","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.2936","article-title":"Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations","volume":"46","author":"Buczkowicz","year":"2014","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.nec.2020.12.001_bib66","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/2159-8290.CD-19-1030","article-title":"Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes","volume":"10","author":"Clarke","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib67","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/s41467-019-12187-5","article-title":"Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas","volume":"10","author":"Guerreiro Stucklin","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.nec.2020.12.001_bib68","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41416-018-0251-2","article-title":"Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma","volume":"119","author":"Ziegler","year":"2018","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.nec.2020.12.001_bib69","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/neuonc\/nov039","article-title":"Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity?","volume":"17","author":"Olsen","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2020.12.001_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228248","article-title":"Unusual high-grade and low-grade glioma in an infant with PPP1CB-ALK gene fusion","volume":"12","author":"Ng","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s10014-018-0330-3","article-title":"Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma","volume":"36","author":"Nakano","year":"2019","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.nec.2020.12.001_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226431","article-title":"A\u00a0novel KIF5B-ALK fusion in a child with an atypical central nervous system inflammatory myofibroblastic tumour","volume":"2018","author":"Maruggi","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3171\/2017.2.PEDS16679","article-title":"Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor","volume":"20","author":"Kiehna","year":"2017","journal-title":"J\u00a0Neurosurg Pediatr"},{"issue":"2","key":"10.1016\/j.nec.2020.12.001_bib74","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/0008-5472.CAN-16-1106","article-title":"Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra","volume":"77","author":"Chmielecki","year":"2017","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.nec.2020.12.001_bib75","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/gcc.22369","article-title":"Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3)","volume":"55","author":"Cocc\u00e9","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.nec.2020.12.001_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217189","article-title":"Novel PPP1CB-ALK fusion protein in a high-grade glioma of infancy","volume":"2016","author":"Aghajan","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"2","key":"10.1016\/j.nec.2020.12.001_bib77","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11060-017-2523-8","article-title":"Molecular landscape of pediatric diffuse intrinsic pontine gliomas: about 22 cases","volume":"134","author":"El Ayoubi","year":"2017","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.nec.2020.12.001_bib78","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1038\/s41467-019-11732-6","article-title":"PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma","volume":"10","author":"Fons","year":"2019","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.nec.2020.12.001_bib79","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1021\/acs.jmedchem.0c00395","article-title":"Targeting ALK2: an open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma","volume":"63","author":"Ensan","year":"2020","journal-title":"J\u00a0Med Chem"},{"issue":"9","key":"10.1016\/j.nec.2020.12.001_bib80","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1541-7786.MCR-16-0389","article-title":"Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG","volume":"15","author":"Cordero","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.nec.2020.12.001_bib81","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noz022","article-title":"Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations","author":"Miklja","year":"2019","journal-title":"Neuro Oncol"}],"container-title":["Neurosurgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104236802030108X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104236802030108X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:01:58Z","timestamp":1760904118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104236802030108X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S104236802030108X"],"URL":"https:\/\/doi.org\/10.1016\/j.nec.2020.12.001","relation":{},"ISSN":["1042-3680"],"issn-type":[{"type":"print","value":"1042-3680"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric Gliomas","name":"articletitle","label":"Article Title"},{"value":"Neurosurgery Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nec.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}